KNSA Earnings

KNSA reported its FY2025Q3 earnings on 2025-10-28, showcasing a revenue of 181.00M against an estimate of 167.00M, resulting in a 8.06% surprise. The EPS was 0, surpassing the expected 0.33 by 0% . The stock experienced a -2.88% price change on the earnings day and a -8.84% change over the next five days, reflecting market reactions to the results.

Following KNSA's FY2025Q3 earnings announcement on 2025-10-28, the stock price moved by -2.88% on the day of the release. Over the subsequent five days, it saw a -8.84% change. Historically, KNSA's stock price tends to shift by an average of -6.01% in the 10 days leading up to earnings and +2.17% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate KNSA’s annual revenue to reach 197.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.11% and EPS estimates Revise Upward by 0.29% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between KNSA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.11%, while EPS estimates moved Revise Upward by 0.29% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, KNSA's stock price typically moves by -6.01% in the 10 days before its earnings and +2.17% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 197.00M.

The earnings call summary and Q&A indicate strong financial performance, positive feedback from patients and physicians, and increased prescriber numbers for ARCALYST. The raised sales guidance for 2025 and strategic marketing efforts further bolster the outlook. Despite some unclear management responses, the overall sentiment is positive, with a focus on growth and market penetration. Given the company's market cap, this is likely to result in a stock price increase of 2% to 8% over the next two weeks.